Dextofisopam

Drug Profile

Dextofisopam

Alternative Names: (R)-tofisopam; Artofisopam; R-tofisopam

Latest Information Update: 24 Jun 2011

Price : $50

At a glance

  • Originator Vela Pharmaceuticals
  • Developer Pharmos Corporation
  • Class Antispasmodics; Anxiolytics; Benzodiazepines; Irritable bowel syndrome therapies; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes - Irritable bowel syndrome

Highest Development Phases

  • Suspended Irritable bowel syndrome

Most Recent Events

  • 28 Oct 2010 Dextofisopam is still available for licensing. www.pharmoscorp.com
  • 14 Sep 2009 Efficacy and adverse events data from a Phase-II trial in Irritable bowel syndrome released by Pharmos Corporation
  • 14 Sep 2009 Pharmos Corporation completes a Phase-IIb trial in Irritable bowel syndrome in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top